Publikationen von D. Lodygin

Lodygin, D.; Tarasov, V.; Epanchintsev, A.; Berking, C.; Knyazeva, T.; Körner, H.; Knyazev, P.; Diebold, J.; Hermeking, H.: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7 (16), S. 2591 - 2600 (2008)

Zhang, W.; Bauer, M.; Croner, R. S.; Pelz, J. O. W.; Lodygin, D.; Hermeking, H.; Sturzl, M.; Hohenberger, W.; Matzel, K. E.: DNA stool test for colorectal cancer: Hypermethylation of the secreted frizzled-related protein-1 gene. Diseases of the Colon & Rectum 50 (10), S. 1618 - 1626 (2007)

Tarasov, V.; Jung, P.; Verdoodt, B.; Lodygin, D.; Epanchintsev, A.; Menssen, A.; Meister, G.; Hermeking, H.: Differential regulation of microRNAs by p53 revealed by massively parallel Sequencing - miR-34a is a p53 target that induces apoptosis and G(1)-arrest. Cell Cycle 6 (13), S. 1586 - 1593 (2007)

Menssen, A.; Epanchintsev, A.; Lodygin, D.; Rezaei, N.; Jung, P.; Verdoodt, B.; Diebold, J.; Hermeking, H.: c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1. Cell Cycle 6 (3), S. 339 - 352 (2007)

Lodygin, D.; Hermeking, H.: Epigenetic silencing of 14-3-3sigma in cancer. Seminars in Cancer Biology 16 (3), S. 214 - 224 (2006)

Lodygin, D.; Epanchintsev, A.; Menssen, A.; Diebold, J.; Hermeking, H.: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Research 65 (10), S. 4218 - 4227 (2005)

Lodygin, D.; Hermeking, H.: The role of epigenetic inactivation of 14-3-3 sigma in human cancer. Cell Research 15 (4), S. 237 - 246 (2005)

Mhawech, P.; Benz, A.; Cerato, C.; Greloz, V.; Assaly, M.; Desmond, J. C.; Koeffler, H. P.; Lodygin, D.; Hermeking, H.; Herrmann, F. et al.; Schwaller, J.: Downregulation of 14-3-3 sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Modern Pathology 18 (3), S. 340 - 348 (2005)

Lodygin, D.; Diebold, J.; Hermeking, H.: Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression. Oncogene 23 (56), S. 9034 - 9041 (2004)

Herzinger, T.; Lodygin, D.; Yazdi, A. S.; Hermeking, H.: Loss of 14-3-3S expression in basal cell carcinoma by epigenetic si-lencing via CPG-methylation. Journal of the American Academy of Dermatology 50 (3 Suppl. Suppl. S), S. P127 - P127 (2004)

Lodygin, D.; Yazdi, A. S.; Sander, C. A.; Herzinger, T.; Hermeking, H.: Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 22 (35), S. 5519 - 5524 (2003)

Lodygin, D.; Menssen, A.; Hermeking, H.: Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. Journal of Clinical Investigation 110 (11), S. 1717 - 1727 (2002)

Lodygin, D.; Menssen, A.-; Hermeking, H.: Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. Journal of Clinical Investigation 110, S. 1717 - 1727 (2002)

Lodygin, D.: Epigenetic and pharmacological regulation of gene expression involved in senescene and tumor progression. Dissertation, Ludwig-Maximilians-Universität, München (2005)